If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,238.00    -5.00 (-0.40%)
Bid:
1,237.00
Ask:
1,240.00
Spread: 3.00 (0.243%)
Market Cap: £855.67m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Response to CMA Summary Final Decision Report

24 Mar 2026 07:13

RNS Number : 8560X
CVS Group plc
24 March 2026
 

For Immediate Release 24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its Final Decision Report in the veterinary services market investigation. The CMA is expected to publish its full Final Decision Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above those announced in its provisional decision. We are pleased to see that the CMA has considered our and the veterinary profession's feedback in amending the proposed fee cap on prescriptions with the cap now increased to £21 inclusive of VAT for the first drug prescribed, with the ability to charge an additional £12.50 for each additional drug prescribed at the same time. Whilst we continue to believe that some of these remedies are not fully justified, we are comfortable with them and believe they are workable. We already comply with many remedies and are well advanced in complying with others, with price lists published on our practice websites in late 2025 and 117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market expectations.

 

Whilst the remedies are now certain and will not change, we look forward to discussing the practical implementation of all remedies with the CMA prior to the publication of its Final Order later in 2026 which will bring these remedies into legal effect.

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPPPURUWUPQUMC
Date   Source Headline
31st Dec 20207:00 amRNSExercise of Options
4th Dec 20209:34 amRNSGrant of Options under SAYE Scheme & PDMR Dealing
26th Nov 20203:49 pmRNSResult of AGM
26th Nov 20207:00 amRNSAGM Statement and Trading Update
23rd Nov 20207:00 amRNSHolding(s) in Company
9th Nov 20201:32 pmRNSLong Term Incentive Plan Awards & PDMR Dealing
6th Nov 20201:46 pmRNSHolding(s) in Company
4th Nov 20202:30 pmRNSPosting of Annual Report & Notice of AGM
30th Oct 20205:09 pmRNSExercise of Options
30th Sep 20207:00 amRNSExercise of Options
24th Sep 20207:00 amRNSFinal Results for the year ended 30 June 2020
4th Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20207:00 amRNSExercise of Options
18th Aug 20203:54 pmRNSHolding(s) in Company
31st Jul 20207:00 amRNSExercise of Options
24th Jul 20207:00 amRNSTrading Update
16th Jul 20207:00 amRNSBoard Appointment
30th Jun 202011:15 amRNSExercise of Options
26th Jun 20207:00 amRNSChange of Company Secretary
9th Jun 202012:29 pmRNSDirector/PDMR Shareholding
1st Jun 202011:50 amRNSExercise of Options
7th May 20209:10 amRNSHolding(s) in Company
30th Apr 202010:25 amRNSExercise of Options
14th Apr 20204:00 pmRNSHolding(s) in Company
9th Apr 202012:23 pmRNSHolding(s) in Company
2nd Apr 20202:29 pmRNSHolding(s) in Company
31st Mar 20201:42 pmRNSExercise of Options
30th Mar 202011:45 amRNSDirector/PDMR Shareholding
27th Mar 20202:52 pmRNSDirector/PDMR Shareholding
27th Mar 202012:02 pmRNSPrice Monitoring Extension
27th Mar 20209:54 amRNSFormatting Replacement: Interim Results
27th Mar 20207:00 amRNSInterim Results
20th Mar 20204:37 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSHolding(s) in Company
12th Mar 20209:34 amRNSHolding(s) in Company
9th Mar 20205:01 pmRNSHolding(s) in Company
9th Mar 20209:18 amRNSHolding(s) in Company
6th Mar 20205:27 pmRNSHolding(s) in Company
6th Mar 20202:47 pmRNSHolding(s) in Company
28th Feb 20207:00 amRNSExercise of Options
7th Feb 20207:00 amRNSTrading Update
31st Jan 20205:47 pmRNSOption exercise and block listing update
27th Jan 20204:12 pmRNSHolding(s) in Company
24th Jan 20204:22 pmRNSHolding(s) in Company
22nd Jan 20205:08 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSHolding(s) in Company
10th Jan 20203:46 pmRNSLong Term Incentive Plan Awards - replacement
10th Jan 20209:27 amRNSHolding(s) in Company
8th Jan 20203:57 pmRNSLong Term Incentive Plan Awards
7th Jan 20204:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.